Henry Krum

57.5k total citations · 14 hit papers
566 papers, 36.9k citations indexed

About

Henry Krum is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Henry Krum has authored 566 papers receiving a total of 36.9k indexed citations (citations by other indexed papers that have themselves been cited), including 442 papers in Cardiology and Cardiovascular Medicine, 113 papers in Endocrinology, Diabetes and Metabolism and 97 papers in Surgery. Recurrent topics in Henry Krum's work include Heart Failure Treatment and Management (216 papers), Blood Pressure and Hypertension Studies (120 papers) and Cardiovascular Function and Risk Factors (110 papers). Henry Krum is often cited by papers focused on Heart Failure Treatment and Management (216 papers), Blood Pressure and Hypertension Studies (120 papers) and Cardiovascular Function and Risk Factors (110 papers). Henry Krum collaborates with scholars based in Australia, United States and United Kingdom. Henry Krum's co-authors include John J.V. McMurray, Markus P. Schlaich, Murray Esler, Faı̈ez Zannad, William T. Abraham, Milton Packer, Dirk J. van Veldhuisen, Paul A. Sobotka, Karl Swedberg and John Vincent and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Henry Krum

553 papers receiving 35.7k citations

Hit Papers

Effect of Carvedilol on S... 2001 2026 2009 2017 2001 2010 2010 2009 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Carvedilol on Survival in Severe Chronic Heart Failure
    2001 2.2k citations Henry Krum et al. profile →
  2. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
    2010 2.0k citations Faı̈ez Zannad, John J.V. McMurray et al. profile →
  3. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
    2010 1.4k citations Murray Esler, Henry Krum et al. profile →
  4. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
    2009 1.4k citations Henry Krum, Markus P. Schlaich et al. profile →
  5. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
    2004 955 citations John J.V. McMurray, Karl Swedberg et al. Circulation profile →
  6. Heart Failure: Preventing Disease and Death Worldwide
    2014 936 citations Piotr Ponikowski, Henry Krum et al. profile →
  7. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
    2002 928 citations Henry Krum et al. Circulation profile →
  8. Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
    2012 909 citations John J.V. McMurray, William T. Abraham et al. European Journal of Heart Failure profile →
  9. Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex
    2013 520 citations William T. Abraham, Jeffrey Borer et al. profile →
  10. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
    2013 447 citations Bertram Pitt, Lars Køber et al. profile →
  11. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
    2013 429 citations Henry Krum, Markus P. Schlaich et al. profile →
  12. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
    2011 399 citations Markus P. Schlaich, Paul A. Sobotka et al. Circulation profile →
  13. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
    2014 363 citations Henry Krum, John G.F. Cleland et al. profile →
  14. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
    2016 299 citations Gerasimos Filippatos, Michael Böhm et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Henry Krum 27.8k 6.8k 5.5k 4.7k 4.0k 566 36.9k
Aldo P. Maggioni 35.8k 1.3× 9.5k 1.4× 8.0k 1.5× 5.4k 1.2× 4.3k 1.1× 873 49.2k
Bertram Pitt 32.5k 1.2× 12.0k 1.8× 9.0k 1.6× 8.7k 1.8× 4.3k 1.1× 578 45.8k
Christopher J. O’Donnell 16.7k 0.6× 5.4k 0.8× 6.9k 1.2× 3.5k 0.7× 6.3k 1.6× 332 37.7k
Michel E. Safar 31.5k 1.1× 5.7k 0.8× 7.0k 1.3× 6.8k 1.5× 1.6k 0.4× 628 39.9k
Javed Butler 29.1k 1.0× 8.1k 1.2× 6.4k 1.2× 6.2k 1.3× 4.5k 1.1× 825 42.1k
Piotr Ponikowski 30.2k 1.1× 6.4k 0.9× 4.7k 0.8× 6.8k 1.5× 4.4k 1.1× 799 44.7k
Guıdo Grassı 23.8k 0.9× 5.3k 0.8× 4.9k 0.9× 1.8k 0.4× 1.8k 0.5× 703 32.3k
Carl J. Pepine 26.1k 0.9× 4.2k 0.6× 11.4k 2.1× 2.8k 0.6× 5.2k 1.3× 907 41.0k
Lars Køber 39.2k 1.4× 10.1k 1.5× 10.5k 1.9× 5.6k 1.2× 6.0k 1.5× 1.4k 59.4k
Gerasimos Filippatos 30.8k 1.1× 7.9k 1.2× 6.3k 1.1× 7.5k 1.6× 5.0k 1.3× 625 43.8k

Countries citing papers authored by Henry Krum

Since Specialization
Citations

This map shows the geographic impact of Henry Krum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Krum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Krum more than expected).

Fields of papers citing papers by Henry Krum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Krum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Krum. The network helps show where Henry Krum may publish in the future.

Co-authorship network of co-authors of Henry Krum

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Krum. A scholar is included among the top collaborators of Henry Krum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Krum. Henry Krum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cannon, Jane A., Timothy Collier, Li Shen, et al.. (2015). Clinical Outcomes According to QRS Duration and Morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 17(7). 707–716. 17 indexed citations
2.
Bello, Natalie A., Eldrin F. Lewis, Akshay S. Desai, et al.. (2015). Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease. European Journal of Heart Failure. 17(11). 1201–1207. 34 indexed citations
3.
Krum, Henry, John J.V. McMurray, William T. Abraham, et al.. (2015). The Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure Trial (Atmosphere): Revised Statistical Analysis Plan and Baseline Characteristics. European Journal of Heart Failure. 17(10). 1075–1083. 14 indexed citations
4.
Cotter, Gad, Marco Metra, Beth A. Davison, et al.. (2014). Worsening Heart Failure, a Critical Event During Hospital Admission for Acute Heart Failure: Results from the VERITAS Study. European Journal of Heart Failure. 16(12). 1362–1371. 23 indexed citations
5.
6.
Lesogor, Anastasia, Jay N. Cohn, Roberto Latini, et al.. (2013). Interaction Between Baseline and Early Worsening of Renal Function and Efficacy of Renin–Angiotensin–Aldosterone System Blockade in Patients with Heart Failure: Insights from the Val-HeFT Study. European Journal of Heart Failure. 15(11). 1236–1244. 45 indexed citations
7.
Esler, Murray, Henry Krum, Markus P. Schlaich, et al.. (2012). Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation. 126(25). 2976–2982. 325 indexed citations
8.
Pitt, Bertram, Gerasimos Filippatos, Mihai Gheorghiade, et al.. (2012). Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease. European Journal of Heart Failure. 14(6). 668–675. 78 indexed citations
9.
Preiss, David, Dirk J. van Veldhuisen, Naveed Sattar, et al.. (2012). Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 14(8). 909–915. 55 indexed citations
10.
Dobre, Daniela, Patrick Rossignol, Ján Murín, et al.. (2012). Statin Therapy and Clinical Outcomes in Myocardial Infarction Patients Complicated by Acute Heart Failure: Insights from the EPHESUS Trial. European Journal of Heart Failure. 15(2). 221–227. 8 indexed citations
11.
Komajda, Michel, Michael Böhm, Jeffrey Borer, et al.. (2012). Influence of Background Treatment with Mineralocorticoid Receptor Antagonists on Ivabradine’s Effects in Patients with Chronic Heart Failure. European Journal of Heart Failure. 15(1). 79–84. 22 indexed citations
12.
Hopper, Ingrid, Marina Skiba, & Henry Krum. (2012). Updated Meta-Analysis on Antithrombotic Therapy in Patients with Heart Failure and Sinus Rhythm. European Journal of Heart Failure. 15(1). 69–78. 24 indexed citations
13.
Zhang, Yuan, Amanda J. Edgley, Alison J. Cox, et al.. (2012). FT011, a New Anti-Fibrotic Drug, Attenuates Fibrosis and Chronic Heart Failure in Experimental Diabetic Cardiomyopathy. European Journal of Heart Failure. 14(5). 549–562. 41 indexed citations
14.
Lu, K., Bryan P. Yan, Andrew E. Ajani, et al.. (2011). Impact of Concomitant Heart Failure on Outcomes in Patients Undergoing Percutaneous Coronary Interventions: Analysis of the Melbourne Interventional Group Registry. European Journal of Heart Failure. 13(4). 416–422. 6 indexed citations
15.
Aronson, Doron, Joseph G. Verbalis, Matthias Müeller, & Henry Krum. (2011). Short- and Long-Term Treatment of Dilutional Hyponatraemia with Satavaptan, a Selective Arginine Vasopressin V2-Receptor Antagonist: The DILIPO Study. European Journal of Heart Failure. 13(3). 327–336. 31 indexed citations
16.
Zannad, Faı̈ez, John J.V. McMurray, Helmut Drexler, et al.. (2010). Rationale and Design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 12(6). 617–622. 56 indexed citations
17.
Schlaich, Markus P., Paul A. Sobotka, Henry Krum, et al.. (2009). Renal Denervation as a Therapeutic Approach for Hypertension. Hypertension. 54(6). 1195–1201. 178 indexed citations
18.
Ritzema, Jay, Iain Melton, Mark Richards, et al.. (2007). Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients. Circulation. 116(25). 2952–2959. 101 indexed citations
19.
Clark, Robyn, Julie Yallop, Leon Piterman, et al.. (2007). Adherence, Adaptation and Acceptance of Elderly Chronic Heart Failure Patients to Receiving Healthcare Via Telephone-Monitoring. European Journal of Heart Failure. 9(11). 1104–1111. 2 indexed citations
20.
Krum, Henry, Julie Hill, Friedrich Fruhwald, et al.. (2005). Tolerability of Beta-Blockers in Elderly Patients with Chronic Heart Failure: The COLA II Study. European Journal of Heart Failure. 8(3). 302–307. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aldo P. Maggioni Breakdown of academic impact, for papers by Bertram Pitt Breakdown of academic impact, for papers by Christopher J. O’Donnell Breakdown of academic impact, for papers by Michel E. Safar Breakdown of academic impact, for papers by Javed Butler Breakdown of academic impact, for papers by Piotr Ponikowski Breakdown of academic impact, for papers by Guıdo Grassı Breakdown of academic impact, for papers by Carl J. Pepine Breakdown of academic impact, for papers by Lars Køber Breakdown of academic impact, for papers by Gerasimos Filippatos
Rankless by CCL
2026